TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02819661

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SOMNOTOUCH RESP
Description: Ventilatory effort recorder

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SOMNOTOUCH RESP
Description: Ventilatory effort recorder

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SOMNOTOUCH RESP
Description: Ventilatory effort recorder

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SOMNOTOUCH RESP
Description: Ventilatory effort recorder
Study: NCT02583048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: For HIV-positive participants only: one 50 mg tablet orally once daily, to be used in combination with two NRTIs until study completion. (NRTIs were not provided by the study.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: For HIV-positive participants only: one 50 mg tablet orally once daily, to be used in combination with two NRTIs until study completion. (NRTIs were not provided by the study.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: For HIV-positive participants only: one 50 mg tablet orally once daily, to be used in combination with two NRTIs until study completion. (NRTIs were not provided by the study.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multidrug Background Treatment (MBT) for TB
Description: A standardized MBT regimen for MDR- or RR-TB except in cases where a participant had known resistance to one of the components of local standard treatment. MBT was provided by the local program.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multidrug Background Treatment (MBT) for TB
Description: A standardized MBT regimen for MDR- or RR-TB except in cases where a participant had known resistance to one of the components of local standard treatment. MBT was provided by the local program.
Study: NCT01090037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRK-100STP low dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00670982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given intravenously every 2 weeks
Study: NCT01591018

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiac surgery
Description: coronary artery bypass graft (CABG) heart valve replacement

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: cardiac surgery
Description: coronary artery bypass graft (CABG) heart valve replacement
Study: NCT00909987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: PO 1000 mg/m2 bid during day 1 to 15 for 3 cycles (every cycle has 3 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV 130 mg/m2 during day 1 for 3 cycles (every cycle has 3 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV 7.5 mg/Kg during 30 minutes day 1 during 4 cycles (every cycle has 3 weeks)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Total dose 50.4 Gy administered during 28 days (1.8 Gy/day in 5 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine during all Radiotherapy period
Description: 825 mg/m2 bid

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Mesorectal Excision (TME)
Description: 4 weeks from the last chemotherapy dose. In those patients who receive radiation TME wil be performed six weeks after
Study: NCT02269059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7680
Description: MK-7680 10 mg and 100 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7680
Description: MK-7680 10 mg and 100 mg capsules
Study: NCT02869867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: refrigerated cushion
Description: refrigerated cushion
Study: NCT00216021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 825 mg/m2 po bid, days 1-14
Study: NCT00216021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 100 mg/m2 IV, day 1
Study: NCT00670982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: Given intravenously once a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: Given intravenously once a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given intravenously once a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given intravenously once a week
Study: NCT04060680

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defibrillation using the Extravascular ICD
Description: VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defibrillation using the Extravascular ICD
Description: VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.
Study: NCT02583048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multidrug Background Treatment (MBT) for TB
Description: A standardized MBT regimen for MDR- or RR-TB except in cases where a participant had known resistance to one of the components of local standard treatment. MBT was provided by the local program.
Study: NCT00736749

Intervention type: PROCEDURE
Intervention: Assessment of Therapy Complications
Description: Complete patient response form and Health Status Update Form

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete patient response form, Health Status Update Form (called the Keep in Touch form), and Quality of Life Questionnaire (PROMIS)
Study: NCT02501733

Intervention type: DEVICE
Group type: OTHER
Intervention: Medacta GMK Sphere® Medial Knee Prosthesis
Description: There is no consensus within the Arthroplasty community as to whether a traditional post and cam-style Posterior Stabilized total knee device is superior to a medial-pivot, more congruent device. However, the majority of surgeons seem to prefer the former, though there is a minority that uses the latter device with great success.~To date, there have been few prospective trials directly comparing these devices, and none with the latest generation of Total Knee Arthroplasty implants. Almost all such studies have been retrospective and/or utilizing older generation devices.
Study: NCT06405321

Intervention type: DRUG
Intervention: Conversion or neoadjuvant therapy.
Description: Patients with hepatocellular carcinoma received conversion or neoadjuvant therapy.
Study: NCT04361630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF 2
Description: Following a standard surgical protocol, rhFGF-2 impregnated membranes will be placed in sites with gingival recession.
Study: NCT04473859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSR Peptide 20μM
Description: Administered immediately after punch-biopsy and 24 hours after punch biopsy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSR Peptide 50μM
Description: Administered immediately after punch-biopsy and 24 hours after punch biopsy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSR Peptide 100μM
Description: Administered immediately after punch-biopsy and 24 hours after punch biopsy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSR Peptide 200μM
Description: Administered immediately after punch-biopsy and 24 hours after punch biopsy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered immediately after punch-biopsy and 24 hours after punch biopsy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered immediately after punch-biopsy and 24 hours after punch biopsy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered immediately after punch-biopsy and 24 hours after punch biopsy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered immediately after punch-biopsy and 24 hours after punch biopsy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered immediately after punch-biopsy and 24 hours after punch biopsy.
Study: NCT01659138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR339658
Description: Pharmaceutical form:solution for infusion~Route of administration: intravenous

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study: NCT05617235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiology taping
Description: On the postoperative 0th day, kinesiology taping was applied to the patients in the study group whose hemodynamic status was stable after extubation by an expert physiotherapist. Investigators applied kinesiology taping as described below:~1. In order to stimulate the facilitation of the diaphragmatic function~2. Taping was applied to the latissimus dorsi and serratus anterior muscles, which were cut during the thoracotomy.~3. In addition, kinesiology taping can be performed on the trigger pain point of the patient .~After 3-4 days, the tape was renewed. Thus, taping was done twice for each patient. The bands were removed at 1 week postoperatively.
Study: NCT04328376

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG coupled to phonocardiography
Description: A standard ECG is recorded along with a phonocardiographic recording. The phonocardiographic recording is obtained by using a specific electronic stethoscope plugged into the auxiliary port of the ECG machine. The recording takes less than 30 seconds. The two recording methods are concomitant.~QT interval is measured on the ECG recording, EMW is measured with ECG coupled to phonocardiography.
Study: NCT01435408

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional primary PCI
Description: Conventional primary PCI in STEMI with implantation of DES.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning.
Description: Primary PCI in STEMI with implantation of DES. Following re-opening of the culprit artery mechanical postconditioning with 4 cycles of 30/30 sec. reperfusion/re-occlusion i performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deferred stenting in primary PCI.
Description: In STEMI re-opening of the artery with guidewire/thrombectomy/small size balloon inflation DES stenting is postponed for 48 hours.
Study: NCT01093573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mutation analysis
Description: Correlative study
Study: NCT00791531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral methotrexate 5mg once daily for 5 consecutive days
Study: NCT02453646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NexSite HD Patients
Description: Measurement of CRBSI rate and other device related adverse events in patients with NexSite HD Catheter.
Study: NCT02886936

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iFIT Transtibial Prosthesis
Description: Transtibial amputee volunteers will be fit with the iFIT device and instructed on its use. Patient will wear the iFIT device for a two week time period according to a provided wear schedule. At the end of this time patient will rate it for comfort, stability and ease of use.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iFIT Transfemoral Prosthesis
Description: Transfemoral amputee volunteers will be fit with the iFIT device and instructed on its use. Patient will wear the iFIT device for a two week time period according to a provided wear schedule. At the end of this time patient will rate it for comfort, stability and ease of use.
Study: NCT03853590

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Description: Creation of a small pouch from the stomach and connection of the newly created pouch directly to the small intestine so that swallowed food bypasses most of the stomach and the first section of the small intestine.
Study: NCT01093573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mutation analysis
Description: Correlative study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mutation analysis
Description: Correlative study
Study: NCT01156987

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: Patients and healthy volunteers will be first screened for MRI contraindications. The SWIFT MRI workflow will be performed as follows:~* an IV line is placed by nurse,~* patient is placed in the 4 T MRI scanner at CMRR,~* initial scout images and manual linear shims are adjusted,~* Pre-contrast SWIFT T1 weighted images and T1 map are obtained,~* continuous SWIFT acquisition begins immediately before contrast injection,~* contrast injection,~* continuous SWIFT acquisition continues for 12 min after contrast,~* late enhancement images may also be obtained.~  10 and 30 patients will be scanned in the first and second year, respectively. Thresholds will be set for prospective analysis. SWIFT-DCE diagnostic performance will be compared to prior FLASH-DCE methods.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: Patients and healthy volunteers will be first screened for MRI contraindications. The SWIFT MRI workflow will be performed as follows:~* an IV line is placed by nurse,~* patient is placed in the 4 T MRI scanner at CMRR,~* initial scout images and manual linear shims are adjusted,~* Pre-contrast SWIFT T1 weighted images and T1 map are obtained,~* continuous SWIFT acquisition begins immediately before contrast injection,~* contrast injection,~* continuous SWIFT acquisition continues for 12 min after contrast,~* late enhancement images may also be obtained.~  10 and 30 patients will be scanned in the first and second year, respectively. Thresholds will be set for prospective analysis. SWIFT-DCE diagnostic performance will be compared to prior FLASH-DCE methods.
Study: NCT03853590

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic adjustable gastric banding
Description: Placement of a soft silicone ring with an expandable balloon in the center, around the top part of the stomach to create a two-compartment stomach, with a much smaller top part above the band. The subject will eat enough food only to fill the top part of the stomach decreasing caloric consumption.
Study: NCT01536353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGSAV301
Description: tablet, q.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exforge 10/160
Description: Tablet, q.d.
Study: NCT03605186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chamomile oral cryotherapy
Description: The infusion of chamomile will be prepared in the clinic with 400 mL of distilled water and 10 g of chamomile flowers (Chamomile classic infusion, Royal Herbs). Patients are asked to swish the chamomile ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session.
Study: NCT01093573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic study
Description: Correlative study: Concentrations of unchanged midostaurin and its major metabolites, CGP52421 and CGP62221 in plasma samples will be determined using a validated liquid chromatography / mass spectrometry method.
Study: NCT00522041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cellegesic
Description: Cellegesic was supplied as an ointment containing 0.4% w/w nitroglycerin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied as an ointment identical to Cellegesic ointment except that it contained no nitroglycerin.
Study: NCT02011451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 95% Pure ECGC capsules 200mg
Description: Theaphenon 95% 95% Pure EGCG

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator:
Study: NCT01430286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psycho-social intervention based on a web-based psycho-educational program, called Diapason.
Description: This group will be trained for a 3 month period by a web-based psycho-educational program, Lifestyle Counseling, etc.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Consultation in memory clinic
Description: This group will receive treatment as usual (consultation in memory clinic every 6 months)
Study: NCT02763696

Intervention type: OTHER
Intervention: Composition of Viginal flora of Child-Bearing women
Description: Use high-throughput sequencing technology to exam Composition of Viginal flora of Child-Bearing women in different menstrual cycle and type of Vaginitis

Intervention type: OTHER
Intervention: Composition of Viginal flora of Child-Bearing women
Description: Use high-throughput sequencing technology to exam Composition of Viginal flora of Child-Bearing women in different menstrual cycle and type of Vaginitis
Study: NCT04715139

Intervention type: DEVICE
Intervention: Products listed in Group/Cohort Description
Description: Depending on approved indication per product
Study: NCT03170739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine given during surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine given during surgery.
Study: NCT03440372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT04489771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Oral administration
Study: NCT03605186

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral cryotherapy
Description: The plain icecubes will be prepared in the clinic with 400 mL of distilled water. Patients are asked to swish the ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session.
Study: NCT01403675

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovarian autotransplantation
Description: There are two ways to transplant the thawed ovarian tissue back into a woman's body. It can be put back inside the abdomen, close to the natural location of the ovaries, or the tissue can be put under the skin of the abdomen. After you have had the transplant, your hormone function will be tested every month. Each month, you will have a blood draw to measure hormones and an ultrasound to see how the tissue is growing. These monthly visits will continue until you have normal hormone levels. If the transplant is successful, it is expected that your hormones would return to normal in 3 - 7 months. If your hormone levels return and stay regular for three months, then Dr. Kim will talk to you about trying to get pregnant. The method of getting pregnant will depend on the type of transplantation surgery you had and your current medical condition. You will have weekly blood tests and other tests to determine the best way to get pregnant.
Study: NCT02546856

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart Failure (HF) nurse up-titration
Description: Up-titration of Beta-Blocker (BB), Angiotensin Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB) and Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure De Novo patients with Left Ventricular Ejection Fraction (LVEF)≤ 40%, following a protocol based on 2012 European Society of Cardiology (ESC) Heart Failure (HF) guidelines with cardiologist prescription and support.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heart Failure (HF) cardiologist up-titration
Description: Up-titration of Beta-Blocker (BB), Angiotensin Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB) and Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure De Novo patients with Left Ventricular Ejection Fraction (LVEF)≤ 40%, following a protocol based on 2012 European Society of Cardiology (ESC) Heart Failure (HF) guidelines. Drugs are prescribed and titrated by the cardiologist.
Study: NCT02298270

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: The Relaxation Response Resiliency Program (3RP) via Skype
Description: 8-week group intervention, delivered via Skype, teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Relaxation Response Resiliency Program (3RP) via Skype
Description: 8-week group intervention, delivered via Skype, teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga.
Study: NCT03015350

Intervention type: DRUG
Intervention: Sevoflurane
Description: Measurement of blood desflurane level during one lung ventilation

Intervention type: DRUG
Intervention: Sevoflurane
Description: Measurement of blood desflurane level during one lung ventilation

Intervention type: DRUG
Intervention: Desflurane
Description: Measurement of blood desflurane level during one lung ventilation

Intervention type: DRUG
Intervention: Desflurane
Description: Measurement of blood desflurane level during one lung ventilation
Study: NCT02324530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Description: CT simulation with and without CPAP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Description: CT simulation with and without CPAP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Description: CT simulation with and without CPAP
Study: NCT03627455

Intervention type: OTHER
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention

Intervention type: OTHER
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention

Intervention type: OTHER
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention

Intervention type: OTHER
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention